nodes	percent_of_prediction	percent_of_DWPC	metapath
Clonidine—CYP1A1—liver cancer	0.568	1	CbGaD
Clonidine—CYP3A5—Sorafenib—liver cancer	0.0416	0.227	CbGbCtD
Clonidine—CYP1A2—Sorafenib—liver cancer	0.0309	0.169	CbGbCtD
Clonidine—ABCB1—Sorafenib—liver cancer	0.0271	0.148	CbGbCtD
Clonidine—CYP2D6—Sorafenib—liver cancer	0.0255	0.139	CbGbCtD
Clonidine—ABCB1—Doxorubicin—liver cancer	0.0164	0.0897	CbGbCtD
Clonidine—CYP3A4—Sorafenib—liver cancer	0.0162	0.0886	CbGbCtD
Clonidine—CYP2D6—Doxorubicin—liver cancer	0.0155	0.0845	CbGbCtD
Clonidine—CYP3A4—Doxorubicin—liver cancer	0.00984	0.0537	CbGbCtD
Clonidine—Rhinorrhoea—Sorafenib—liver cancer	0.00223	0.0199	CcSEcCtD
Clonidine—Endocrine disorder—Sorafenib—liver cancer	0.00218	0.0195	CcSEcCtD
Clonidine—Sensitisation—Epirubicin—liver cancer	0.00187	0.0167	CcSEcCtD
Clonidine—Influenza like illness—Sorafenib—liver cancer	0.00176	0.0157	CcSEcCtD
Clonidine—Sensitisation—Doxorubicin—liver cancer	0.00173	0.0154	CcSEcCtD
Clonidine—Gynaecomastia—Sorafenib—liver cancer	0.00162	0.0144	CcSEcCtD
Clonidine—Cardiac failure congestive—Sorafenib—liver cancer	0.00145	0.0129	CcSEcCtD
Clonidine—Pain in extremity—Sorafenib—liver cancer	0.00131	0.0117	CcSEcCtD
Clonidine—Abdominal pain upper—Sorafenib—liver cancer	0.0012	0.0107	CcSEcCtD
Clonidine—Breast disorder—Sorafenib—liver cancer	0.00119	0.0106	CcSEcCtD
Clonidine—Nasopharyngitis—Sorafenib—liver cancer	0.00117	0.0105	CcSEcCtD
Clonidine—Skin hyperpigmentation—Epirubicin—liver cancer	0.00112	0.01	CcSEcCtD
Clonidine—Erectile dysfunction—Sorafenib—liver cancer	0.00104	0.00932	CcSEcCtD
Clonidine—Skin hyperpigmentation—Doxorubicin—liver cancer	0.00104	0.00927	CcSEcCtD
Clonidine—Epistaxis—Sorafenib—liver cancer	0.000954	0.00851	CcSEcCtD
Clonidine—Ileus—Epirubicin—liver cancer	0.000944	0.00842	CcSEcCtD
Clonidine—Ileus—Doxorubicin—liver cancer	0.000874	0.00779	CcSEcCtD
Clonidine—Skin ulcer—Epirubicin—liver cancer	0.000858	0.00766	CcSEcCtD
Clonidine—Hyperaesthesia—Epirubicin—liver cancer	0.000851	0.00759	CcSEcCtD
Clonidine—Tinnitus—Sorafenib—liver cancer	0.000847	0.00755	CcSEcCtD
Clonidine—Cardiac disorder—Sorafenib—liver cancer	0.000843	0.00752	CcSEcCtD
Clonidine—Angiopathy—Sorafenib—liver cancer	0.000824	0.00735	CcSEcCtD
Clonidine—Mediastinal disorder—Sorafenib—liver cancer	0.000818	0.0073	CcSEcCtD
Clonidine—Arrhythmia—Sorafenib—liver cancer	0.000811	0.00723	CcSEcCtD
Clonidine—Alopecia—Sorafenib—liver cancer	0.000802	0.00716	CcSEcCtD
Clonidine—Mental disorder—Sorafenib—liver cancer	0.000796	0.0071	CcSEcCtD
Clonidine—Skin ulcer—Doxorubicin—liver cancer	0.000794	0.00708	CcSEcCtD
Clonidine—Erythema—Sorafenib—liver cancer	0.00079	0.00705	CcSEcCtD
Clonidine—Hyperaesthesia—Doxorubicin—liver cancer	0.000788	0.00703	CcSEcCtD
Clonidine—Delirium—Epirubicin—liver cancer	0.000777	0.00693	CcSEcCtD
Clonidine—Muscle spasms—Sorafenib—liver cancer	0.00076	0.00678	CcSEcCtD
Clonidine—Angioedema—Sorafenib—liver cancer	0.000722	0.00644	CcSEcCtD
Clonidine—Nocturia—Epirubicin—liver cancer	0.00072	0.00642	CcSEcCtD
Clonidine—Delirium—Doxorubicin—liver cancer	0.000719	0.00641	CcSEcCtD
Clonidine—Syncope—Sorafenib—liver cancer	0.000709	0.00632	CcSEcCtD
Clonidine—Loss of consciousness—Sorafenib—liver cancer	0.000695	0.0062	CcSEcCtD
Clonidine—Cough—Sorafenib—liver cancer	0.00069	0.00615	CcSEcCtD
Clonidine—Atrioventricular block—Epirubicin—liver cancer	0.000689	0.00614	CcSEcCtD
Clonidine—Arthralgia—Sorafenib—liver cancer	0.000673	0.006	CcSEcCtD
Clonidine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000668	0.00596	CcSEcCtD
Clonidine—Nocturia—Doxorubicin—liver cancer	0.000667	0.00594	CcSEcCtD
Clonidine—Abnormal dreams—Epirubicin—liver cancer	0.00066	0.00589	CcSEcCtD
Clonidine—Dermatitis contact—Epirubicin—liver cancer	0.00066	0.00589	CcSEcCtD
Clonidine—Dry mouth—Sorafenib—liver cancer	0.000658	0.00587	CcSEcCtD
Clonidine—Influenza like illness—Epirubicin—liver cancer	0.000649	0.00579	CcSEcCtD
Clonidine—Infection—Sorafenib—liver cancer	0.000641	0.00572	CcSEcCtD
Clonidine—Atrioventricular block—Doxorubicin—liver cancer	0.000637	0.00569	CcSEcCtD
Clonidine—Shock—Sorafenib—liver cancer	0.000635	0.00566	CcSEcCtD
Clonidine—Nervous system disorder—Sorafenib—liver cancer	0.000633	0.00564	CcSEcCtD
Clonidine—Thrombocytopenia—Sorafenib—liver cancer	0.000632	0.00563	CcSEcCtD
Clonidine—Skin disorder—Sorafenib—liver cancer	0.000627	0.00559	CcSEcCtD
Clonidine—Dry eye—Epirubicin—liver cancer	0.000617	0.0055	CcSEcCtD
Clonidine—Anorexia—Sorafenib—liver cancer	0.000615	0.00548	CcSEcCtD
Clonidine—Cramps of lower extremities—Epirubicin—liver cancer	0.000614	0.00548	CcSEcCtD
Clonidine—Dermatitis contact—Doxorubicin—liver cancer	0.000611	0.00545	CcSEcCtD
Clonidine—Abnormal dreams—Doxorubicin—liver cancer	0.000611	0.00545	CcSEcCtD
Clonidine—Rash maculo-papular—Epirubicin—liver cancer	0.000607	0.00542	CcSEcCtD
Clonidine—Influenza like illness—Doxorubicin—liver cancer	0.000601	0.00536	CcSEcCtD
Clonidine—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000588	0.00524	CcSEcCtD
Clonidine—Dyspnoea—Sorafenib—liver cancer	0.000575	0.00513	CcSEcCtD
Clonidine—Dry eye—Doxorubicin—liver cancer	0.000571	0.00509	CcSEcCtD
Clonidine—Cramps of lower extremities—Doxorubicin—liver cancer	0.000568	0.00507	CcSEcCtD
Clonidine—Rash maculo-papular—Doxorubicin—liver cancer	0.000562	0.00501	CcSEcCtD
Clonidine—Decreased appetite—Sorafenib—liver cancer	0.000561	0.005	CcSEcCtD
Clonidine—Gastrointestinal disorder—Sorafenib—liver cancer	0.000557	0.00497	CcSEcCtD
Clonidine—Fatigue—Sorafenib—liver cancer	0.000556	0.00496	CcSEcCtD
Clonidine—Pain—Sorafenib—liver cancer	0.000552	0.00492	CcSEcCtD
Clonidine—Constipation—Sorafenib—liver cancer	0.000552	0.00492	CcSEcCtD
Clonidine—Diclofenac—CYP2E1—liver cancer	0.000535	0.394	CrCbGaD
Clonidine—Cardiac failure congestive—Epirubicin—liver cancer	0.000535	0.00477	CcSEcCtD
Clonidine—Diclofenac—CYP1A1—liver cancer	0.000528	0.389	CrCbGaD
Clonidine—Gastrointestinal pain—Sorafenib—liver cancer	0.000528	0.0047	CcSEcCtD
Clonidine—Urticaria—Sorafenib—liver cancer	0.000513	0.00457	CcSEcCtD
Clonidine—Abdominal pain—Sorafenib—liver cancer	0.00051	0.00455	CcSEcCtD
Clonidine—Body temperature increased—Sorafenib—liver cancer	0.00051	0.00455	CcSEcCtD
Clonidine—Lethargy—Epirubicin—liver cancer	0.000495	0.00441	CcSEcCtD
Clonidine—Cerebrovascular accident—Epirubicin—liver cancer	0.000495	0.00441	CcSEcCtD
Clonidine—Cardiac failure congestive—Doxorubicin—liver cancer	0.000495	0.00441	CcSEcCtD
Clonidine—Pain in extremity—Epirubicin—liver cancer	0.000485	0.00433	CcSEcCtD
Clonidine—Hypersensitivity—Sorafenib—liver cancer	0.000475	0.00424	CcSEcCtD
Clonidine—Asthenia—Sorafenib—liver cancer	0.000463	0.00413	CcSEcCtD
Clonidine—Lethargy—Doxorubicin—liver cancer	0.000458	0.00408	CcSEcCtD
Clonidine—Cerebrovascular accident—Doxorubicin—liver cancer	0.000458	0.00408	CcSEcCtD
Clonidine—Pruritus—Sorafenib—liver cancer	0.000456	0.00407	CcSEcCtD
Clonidine—Pain in extremity—Doxorubicin—liver cancer	0.000449	0.004	CcSEcCtD
Clonidine—Liver function test abnormal—Epirubicin—liver cancer	0.000448	0.00399	CcSEcCtD
Clonidine—Orthostatic hypotension—Epirubicin—liver cancer	0.000443	0.00395	CcSEcCtD
Clonidine—Abdominal pain upper—Epirubicin—liver cancer	0.000443	0.00395	CcSEcCtD
Clonidine—Diarrhoea—Sorafenib—liver cancer	0.000441	0.00394	CcSEcCtD
Clonidine—Breast disorder—Epirubicin—liver cancer	0.000438	0.00391	CcSEcCtD
Clonidine—Nasopharyngitis—Epirubicin—liver cancer	0.000434	0.00387	CcSEcCtD
Clonidine—Dizziness—Sorafenib—liver cancer	0.000427	0.0038	CcSEcCtD
Clonidine—Asthma—Epirubicin—liver cancer	0.000419	0.00374	CcSEcCtD
Clonidine—Liver function test abnormal—Doxorubicin—liver cancer	0.000414	0.0037	CcSEcCtD
Clonidine—Vomiting—Sorafenib—liver cancer	0.00041	0.00366	CcSEcCtD
Clonidine—Orthostatic hypotension—Doxorubicin—liver cancer	0.00041	0.00366	CcSEcCtD
Clonidine—Abdominal pain upper—Doxorubicin—liver cancer	0.00041	0.00366	CcSEcCtD
Clonidine—Rash—Sorafenib—liver cancer	0.000407	0.00363	CcSEcCtD
Clonidine—Dermatitis—Sorafenib—liver cancer	0.000406	0.00362	CcSEcCtD
Clonidine—Breast disorder—Doxorubicin—liver cancer	0.000406	0.00362	CcSEcCtD
Clonidine—Headache—Sorafenib—liver cancer	0.000404	0.0036	CcSEcCtD
Clonidine—Nasopharyngitis—Doxorubicin—liver cancer	0.000401	0.00358	CcSEcCtD
Clonidine—Dysuria—Epirubicin—liver cancer	0.000392	0.0035	CcSEcCtD
Clonidine—Upper respiratory tract infection—Epirubicin—liver cancer	0.00039	0.00348	CcSEcCtD
Clonidine—Asthma—Doxorubicin—liver cancer	0.000388	0.00346	CcSEcCtD
Clonidine—Pollakiuria—Epirubicin—liver cancer	0.000387	0.00345	CcSEcCtD
Clonidine—Nausea—Sorafenib—liver cancer	0.000383	0.00342	CcSEcCtD
Clonidine—Weight increased—Epirubicin—liver cancer	0.000382	0.0034	CcSEcCtD
Clonidine—Drowsiness—Epirubicin—liver cancer	0.000374	0.00333	CcSEcCtD
Clonidine—Urinary tract infection—Epirubicin—liver cancer	0.000363	0.00324	CcSEcCtD
Clonidine—Dysuria—Doxorubicin—liver cancer	0.000363	0.00324	CcSEcCtD
Clonidine—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000361	0.00322	CcSEcCtD
Clonidine—Sweating—Epirubicin—liver cancer	0.000358	0.0032	CcSEcCtD
Clonidine—Pollakiuria—Doxorubicin—liver cancer	0.000358	0.0032	CcSEcCtD
Clonidine—Weight increased—Doxorubicin—liver cancer	0.000353	0.00315	CcSEcCtD
Clonidine—Epistaxis—Epirubicin—liver cancer	0.000353	0.00314	CcSEcCtD
Clonidine—Drowsiness—Doxorubicin—liver cancer	0.000346	0.00308	CcSEcCtD
Clonidine—Bradycardia—Epirubicin—liver cancer	0.000342	0.00305	CcSEcCtD
Clonidine—Rhinitis—Epirubicin—liver cancer	0.000336	0.003	CcSEcCtD
Clonidine—Urinary tract infection—Doxorubicin—liver cancer	0.000336	0.003	CcSEcCtD
Clonidine—Hepatitis—Epirubicin—liver cancer	0.000336	0.00299	CcSEcCtD
Clonidine—Hypoaesthesia—Epirubicin—liver cancer	0.000334	0.00298	CcSEcCtD
Clonidine—Sweating—Doxorubicin—liver cancer	0.000332	0.00296	CcSEcCtD
Clonidine—Epistaxis—Doxorubicin—liver cancer	0.000326	0.00291	CcSEcCtD
Clonidine—Bradycardia—Doxorubicin—liver cancer	0.000316	0.00282	CcSEcCtD
Clonidine—Eye disorder—Epirubicin—liver cancer	0.000314	0.0028	CcSEcCtD
Clonidine—Tinnitus—Epirubicin—liver cancer	0.000313	0.00279	CcSEcCtD
Clonidine—Cardiac disorder—Epirubicin—liver cancer	0.000311	0.00278	CcSEcCtD
Clonidine—Rhinitis—Doxorubicin—liver cancer	0.000311	0.00278	CcSEcCtD
Clonidine—Hepatitis—Doxorubicin—liver cancer	0.000311	0.00277	CcSEcCtD
Clonidine—Hypoaesthesia—Doxorubicin—liver cancer	0.000309	0.00276	CcSEcCtD
Clonidine—Angiopathy—Epirubicin—liver cancer	0.000304	0.00272	CcSEcCtD
Clonidine—Mediastinal disorder—Epirubicin—liver cancer	0.000302	0.0027	CcSEcCtD
Clonidine—Arrhythmia—Epirubicin—liver cancer	0.0003	0.00267	CcSEcCtD
Clonidine—Alopecia—Epirubicin—liver cancer	0.000297	0.00264	CcSEcCtD
Clonidine—Mental disorder—Epirubicin—liver cancer	0.000294	0.00262	CcSEcCtD
Clonidine—Diclofenac—ALB—liver cancer	0.000294	0.217	CrCbGaD
Clonidine—Erythema—Epirubicin—liver cancer	0.000292	0.00261	CcSEcCtD
Clonidine—Eye disorder—Doxorubicin—liver cancer	0.00029	0.00259	CcSEcCtD
Clonidine—Tinnitus—Doxorubicin—liver cancer	0.00029	0.00258	CcSEcCtD
Clonidine—Cardiac disorder—Doxorubicin—liver cancer	0.000288	0.00257	CcSEcCtD
Clonidine—Tension—Epirubicin—liver cancer	0.000287	0.00256	CcSEcCtD
Clonidine—Nervousness—Epirubicin—liver cancer	0.000284	0.00253	CcSEcCtD
Clonidine—Angiopathy—Doxorubicin—liver cancer	0.000282	0.00251	CcSEcCtD
Clonidine—Muscle spasms—Epirubicin—liver cancer	0.000281	0.0025	CcSEcCtD
Clonidine—Mediastinal disorder—Doxorubicin—liver cancer	0.00028	0.0025	CcSEcCtD
Clonidine—Arrhythmia—Doxorubicin—liver cancer	0.000277	0.00247	CcSEcCtD
Clonidine—Vision blurred—Epirubicin—liver cancer	0.000275	0.00246	CcSEcCtD
Clonidine—Alopecia—Doxorubicin—liver cancer	0.000274	0.00245	CcSEcCtD
Clonidine—Mental disorder—Doxorubicin—liver cancer	0.000272	0.00243	CcSEcCtD
Clonidine—Ill-defined disorder—Epirubicin—liver cancer	0.000271	0.00242	CcSEcCtD
Clonidine—Erythema—Doxorubicin—liver cancer	0.00027	0.00241	CcSEcCtD
Clonidine—Agitation—Epirubicin—liver cancer	0.000268	0.00239	CcSEcCtD
Clonidine—Tension—Doxorubicin—liver cancer	0.000265	0.00237	CcSEcCtD
Clonidine—Malaise—Epirubicin—liver cancer	0.000263	0.00235	CcSEcCtD
Clonidine—Nervousness—Doxorubicin—liver cancer	0.000263	0.00234	CcSEcCtD
Clonidine—Syncope—Epirubicin—liver cancer	0.000262	0.00234	CcSEcCtD
Clonidine—Muscle spasms—Doxorubicin—liver cancer	0.00026	0.00232	CcSEcCtD
Clonidine—Palpitations—Epirubicin—liver cancer	0.000258	0.0023	CcSEcCtD
Clonidine—Loss of consciousness—Epirubicin—liver cancer	0.000257	0.00229	CcSEcCtD
Clonidine—Cough—Epirubicin—liver cancer	0.000255	0.00227	CcSEcCtD
Clonidine—Vision blurred—Doxorubicin—liver cancer	0.000255	0.00227	CcSEcCtD
Clonidine—Ill-defined disorder—Doxorubicin—liver cancer	0.000251	0.00224	CcSEcCtD
Clonidine—Arthralgia—Epirubicin—liver cancer	0.000249	0.00222	CcSEcCtD
Clonidine—Chest pain—Epirubicin—liver cancer	0.000249	0.00222	CcSEcCtD
Clonidine—Agitation—Doxorubicin—liver cancer	0.000248	0.00222	CcSEcCtD
Clonidine—Anxiety—Epirubicin—liver cancer	0.000248	0.00221	CcSEcCtD
Clonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000247	0.0022	CcSEcCtD
Clonidine—Discomfort—Epirubicin—liver cancer	0.000246	0.00219	CcSEcCtD
Clonidine—Malaise—Doxorubicin—liver cancer	0.000244	0.00217	CcSEcCtD
Clonidine—Dry mouth—Epirubicin—liver cancer	0.000243	0.00217	CcSEcCtD
Clonidine—Syncope—Doxorubicin—liver cancer	0.000242	0.00216	CcSEcCtD
Clonidine—Confusional state—Epirubicin—liver cancer	0.00024	0.00214	CcSEcCtD
Clonidine—Palpitations—Doxorubicin—liver cancer	0.000239	0.00213	CcSEcCtD
Clonidine—Oedema—Epirubicin—liver cancer	0.000238	0.00213	CcSEcCtD
Clonidine—Loss of consciousness—Doxorubicin—liver cancer	0.000238	0.00212	CcSEcCtD
Clonidine—Infection—Epirubicin—liver cancer	0.000237	0.00211	CcSEcCtD
Clonidine—Cough—Doxorubicin—liver cancer	0.000236	0.0021	CcSEcCtD
Clonidine—Shock—Epirubicin—liver cancer	0.000235	0.00209	CcSEcCtD
Clonidine—Nervous system disorder—Epirubicin—liver cancer	0.000234	0.00209	CcSEcCtD
Clonidine—Thrombocytopenia—Epirubicin—liver cancer	0.000233	0.00208	CcSEcCtD
Clonidine—Tachycardia—Epirubicin—liver cancer	0.000233	0.00208	CcSEcCtD
Clonidine—Skin disorder—Epirubicin—liver cancer	0.000232	0.00207	CcSEcCtD
Clonidine—Hyperhidrosis—Epirubicin—liver cancer	0.00023	0.00206	CcSEcCtD
Clonidine—Arthralgia—Doxorubicin—liver cancer	0.00023	0.00205	CcSEcCtD
Clonidine—Chest pain—Doxorubicin—liver cancer	0.00023	0.00205	CcSEcCtD
Clonidine—Anxiety—Doxorubicin—liver cancer	0.000229	0.00205	CcSEcCtD
Clonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000229	0.00204	CcSEcCtD
Clonidine—Discomfort—Doxorubicin—liver cancer	0.000227	0.00203	CcSEcCtD
Clonidine—Anorexia—Epirubicin—liver cancer	0.000227	0.00203	CcSEcCtD
Clonidine—Dry mouth—Doxorubicin—liver cancer	0.000225	0.00201	CcSEcCtD
Clonidine—Hypotension—Epirubicin—liver cancer	0.000223	0.00199	CcSEcCtD
Clonidine—Confusional state—Doxorubicin—liver cancer	0.000222	0.00198	CcSEcCtD
Clonidine—Oedema—Doxorubicin—liver cancer	0.000221	0.00197	CcSEcCtD
Clonidine—Infection—Doxorubicin—liver cancer	0.000219	0.00195	CcSEcCtD
Clonidine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000217	0.00194	CcSEcCtD
Clonidine—Shock—Doxorubicin—liver cancer	0.000217	0.00194	CcSEcCtD
Clonidine—Nervous system disorder—Doxorubicin—liver cancer	0.000216	0.00193	CcSEcCtD
Clonidine—Thrombocytopenia—Doxorubicin—liver cancer	0.000216	0.00193	CcSEcCtD
Clonidine—Insomnia—Epirubicin—liver cancer	0.000216	0.00192	CcSEcCtD
Clonidine—Tachycardia—Doxorubicin—liver cancer	0.000215	0.00192	CcSEcCtD
Clonidine—Skin disorder—Doxorubicin—liver cancer	0.000214	0.00191	CcSEcCtD
Clonidine—Paraesthesia—Epirubicin—liver cancer	0.000214	0.00191	CcSEcCtD
Clonidine—Hyperhidrosis—Doxorubicin—liver cancer	0.000213	0.0019	CcSEcCtD
Clonidine—Dyspnoea—Epirubicin—liver cancer	0.000213	0.0019	CcSEcCtD
Clonidine—Somnolence—Epirubicin—liver cancer	0.000212	0.00189	CcSEcCtD
Clonidine—Anorexia—Doxorubicin—liver cancer	0.00021	0.00188	CcSEcCtD
Clonidine—Decreased appetite—Epirubicin—liver cancer	0.000207	0.00185	CcSEcCtD
Clonidine—Hypotension—Doxorubicin—liver cancer	0.000206	0.00184	CcSEcCtD
Clonidine—Gastrointestinal disorder—Epirubicin—liver cancer	0.000206	0.00184	CcSEcCtD
Clonidine—Fatigue—Epirubicin—liver cancer	0.000206	0.00183	CcSEcCtD
Clonidine—Constipation—Epirubicin—liver cancer	0.000204	0.00182	CcSEcCtD
Clonidine—Pain—Epirubicin—liver cancer	0.000204	0.00182	CcSEcCtD
Clonidine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000201	0.00179	CcSEcCtD
Clonidine—Insomnia—Doxorubicin—liver cancer	0.0002	0.00178	CcSEcCtD
Clonidine—Paraesthesia—Doxorubicin—liver cancer	0.000198	0.00177	CcSEcCtD
Clonidine—Dyspnoea—Doxorubicin—liver cancer	0.000197	0.00175	CcSEcCtD
Clonidine—Feeling abnormal—Epirubicin—liver cancer	0.000196	0.00175	CcSEcCtD
Clonidine—Somnolence—Doxorubicin—liver cancer	0.000196	0.00175	CcSEcCtD
Clonidine—Gastrointestinal pain—Epirubicin—liver cancer	0.000195	0.00174	CcSEcCtD
Clonidine—Decreased appetite—Doxorubicin—liver cancer	0.000192	0.00171	CcSEcCtD
Clonidine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00019	0.0017	CcSEcCtD
Clonidine—Fatigue—Doxorubicin—liver cancer	0.00019	0.0017	CcSEcCtD
Clonidine—Urticaria—Epirubicin—liver cancer	0.000189	0.00169	CcSEcCtD
Clonidine—Pain—Doxorubicin—liver cancer	0.000189	0.00168	CcSEcCtD
Clonidine—Constipation—Doxorubicin—liver cancer	0.000189	0.00168	CcSEcCtD
Clonidine—Abdominal pain—Epirubicin—liver cancer	0.000188	0.00168	CcSEcCtD
Clonidine—Body temperature increased—Epirubicin—liver cancer	0.000188	0.00168	CcSEcCtD
Clonidine—Feeling abnormal—Doxorubicin—liver cancer	0.000182	0.00162	CcSEcCtD
Clonidine—Gastrointestinal pain—Doxorubicin—liver cancer	0.00018	0.00161	CcSEcCtD
Clonidine—Hypersensitivity—Epirubicin—liver cancer	0.000176	0.00157	CcSEcCtD
Clonidine—Urticaria—Doxorubicin—liver cancer	0.000175	0.00156	CcSEcCtD
Clonidine—Body temperature increased—Doxorubicin—liver cancer	0.000174	0.00156	CcSEcCtD
Clonidine—Abdominal pain—Doxorubicin—liver cancer	0.000174	0.00156	CcSEcCtD
Clonidine—Asthenia—Epirubicin—liver cancer	0.000171	0.00153	CcSEcCtD
Clonidine—Pruritus—Epirubicin—liver cancer	0.000169	0.0015	CcSEcCtD
Clonidine—Diarrhoea—Epirubicin—liver cancer	0.000163	0.00145	CcSEcCtD
Clonidine—Hypersensitivity—Doxorubicin—liver cancer	0.000163	0.00145	CcSEcCtD
Clonidine—Asthenia—Doxorubicin—liver cancer	0.000158	0.00141	CcSEcCtD
Clonidine—Dizziness—Epirubicin—liver cancer	0.000158	0.00141	CcSEcCtD
Clonidine—Pruritus—Doxorubicin—liver cancer	0.000156	0.00139	CcSEcCtD
Clonidine—Vomiting—Epirubicin—liver cancer	0.000152	0.00135	CcSEcCtD
Clonidine—Diarrhoea—Doxorubicin—liver cancer	0.000151	0.00135	CcSEcCtD
Clonidine—Rash—Epirubicin—liver cancer	0.00015	0.00134	CcSEcCtD
Clonidine—Dermatitis—Epirubicin—liver cancer	0.00015	0.00134	CcSEcCtD
Clonidine—Headache—Epirubicin—liver cancer	0.000149	0.00133	CcSEcCtD
Clonidine—Dizziness—Doxorubicin—liver cancer	0.000146	0.0013	CcSEcCtD
Clonidine—Nausea—Epirubicin—liver cancer	0.000142	0.00126	CcSEcCtD
Clonidine—Vomiting—Doxorubicin—liver cancer	0.00014	0.00125	CcSEcCtD
Clonidine—Rash—Doxorubicin—liver cancer	0.000139	0.00124	CcSEcCtD
Clonidine—Dermatitis—Doxorubicin—liver cancer	0.000139	0.00124	CcSEcCtD
Clonidine—Headache—Doxorubicin—liver cancer	0.000138	0.00123	CcSEcCtD
Clonidine—Nausea—Doxorubicin—liver cancer	0.000131	0.00117	CcSEcCtD
Clonidine—ABCB1—Metabolism—CYP1A1—liver cancer	9.61e-06	7.08e-05	CbGpPWpGaD
Clonidine—ADRA1B—GPCR downstream signaling—PIK3CA—liver cancer	9.6e-06	7.08e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—SERPINE1—liver cancer	9.59e-06	7.07e-05	CbGpPWpGaD
Clonidine—ADRA2A—Metabolism—PIK3CD—liver cancer	9.57e-06	7.05e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—CDKN1B—liver cancer	9.56e-06	7.04e-05	CbGpPWpGaD
Clonidine—CYP2D6—Metabolism—GSTM1—liver cancer	9.55e-06	7.04e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—F2—liver cancer	9.51e-06	7.01e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling by GPCR—KRAS—liver cancer	9.49e-06	7e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling by GPCR—PIK3CA—liver cancer	9.49e-06	6.99e-05	CbGpPWpGaD
Clonidine—ADRA1D—GPCR downstream signaling—AKT1—liver cancer	9.45e-06	6.97e-05	CbGpPWpGaD
Clonidine—ADRA2A—Metabolism—ALB—liver cancer	9.45e-06	6.96e-05	CbGpPWpGaD
Clonidine—CYP1A1—Metabolism—PIK3CG—liver cancer	9.42e-06	6.95e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—RAF1—liver cancer	9.42e-06	6.94e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—CASP3—liver cancer	9.37e-06	6.9e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—IL2—liver cancer	9.35e-06	6.89e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling by GPCR—IL6—liver cancer	9.3e-06	6.86e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—BRAF—liver cancer	9.21e-06	6.79e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—MTOR—liver cancer	9.19e-06	6.77e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—PIK3CB—liver cancer	9.19e-06	6.77e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—CCND1—liver cancer	9.12e-06	6.72e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—APC—liver cancer	9.1e-06	6.71e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—PIK3CG—liver cancer	9.1e-06	6.71e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—JUN—liver cancer	9.1e-06	6.7e-05	CbGpPWpGaD
Clonidine—CYP1A1—Metabolism—PPARG—liver cancer	9.1e-06	6.7e-05	CbGpPWpGaD
Clonidine—CYP2D6—Metabolism—CYP1A1—liver cancer	9.06e-06	6.67e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—CTNNB1—liver cancer	9.03e-06	6.65e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—PSMA4—liver cancer	9.01e-06	6.64e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—PSMD10—liver cancer	9.01e-06	6.64e-05	CbGpPWpGaD
Clonidine—ABCB1—Metabolism—MTHFR—liver cancer	8.96e-06	6.6e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling by GPCR—PIK3CA—liver cancer	8.86e-06	6.53e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—MMP9—liver cancer	8.85e-06	6.52e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—CDKN1A—liver cancer	8.82e-06	6.5e-05	CbGpPWpGaD
Clonidine—CYP1A2—Metabolism—GSTP1—liver cancer	8.81e-06	6.49e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—RAF1—liver cancer	8.8e-06	6.48e-05	CbGpPWpGaD
Clonidine—ABCB1—Metabolism—PPARA—liver cancer	8.79e-06	6.48e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling by GPCR—HRAS—liver cancer	8.78e-06	6.47e-05	CbGpPWpGaD
Clonidine—CYP3A5—Metabolism—PIK3CD—liver cancer	8.77e-06	6.46e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—GOT2—liver cancer	8.77e-06	6.46e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling by GPCR—PIK3CA—liver cancer	8.72e-06	6.43e-05	CbGpPWpGaD
Clonidine—CYP1A2—Metabolism—HMOX1—liver cancer	8.69e-06	6.4e-05	CbGpPWpGaD
Clonidine—CYP3A5—Metabolism—ALB—liver cancer	8.66e-06	6.38e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—RAF1—liver cancer	8.66e-06	6.38e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—CDKN1B—liver cancer	8.63e-06	6.36e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—PIK3CD—liver cancer	8.61e-06	6.35e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—MAPK8—liver cancer	8.61e-06	6.34e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—PIK3CB—liver cancer	8.59e-06	6.33e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—MTOR—liver cancer	8.59e-06	6.33e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling by GPCR—AKT1—liver cancer	8.58e-06	6.33e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—BRAF—liver cancer	8.56e-06	6.31e-05	CbGpPWpGaD
Clonidine—ADRA2B—GPCR downstream signaling—AKT1—liver cancer	8.53e-06	6.29e-05	CbGpPWpGaD
Clonidine—ADRA1A—GPCR downstream signaling—PIK3CA—liver cancer	8.53e-06	6.29e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—SERPINE1—liver cancer	8.52e-06	6.28e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—CASP3—liver cancer	8.46e-06	6.23e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—PIK3CB—liver cancer	8.45e-06	6.23e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—MTOR—liver cancer	8.45e-06	6.23e-05	CbGpPWpGaD
Clonidine—CYP2D6—Metabolism—MTHFR—liver cancer	8.44e-06	6.22e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—IL2—liver cancer	8.44e-06	6.22e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling by GPCR—KRAS—liver cancer	8.43e-06	6.21e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling by GPCR—IL6—liver cancer	8.4e-06	6.19e-05	CbGpPWpGaD
Clonidine—SLC22A3—Metabolism—AKT1—liver cancer	8.38e-06	6.18e-05	CbGpPWpGaD
Clonidine—ADRA2A—Metabolism—PIK3CB—liver cancer	8.34e-06	6.15e-05	CbGpPWpGaD
Clonidine—CYP1A1—Metabolism—PIK3CD—liver cancer	8.29e-06	6.11e-05	CbGpPWpGaD
Clonidine—CYP2D6—Metabolism—PPARA—liver cancer	8.28e-06	6.1e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—CYP2E1—liver cancer	8.24e-06	6.07e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—CCND1—liver cancer	8.23e-06	6.07e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—JUN—liver cancer	8.21e-06	6.05e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling by GPCR—HRAS—liver cancer	8.2e-06	6.04e-05	CbGpPWpGaD
Clonidine—CYP1A1—Metabolism—ALB—liver cancer	8.18e-06	6.03e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—CTNNB1—liver cancer	8.15e-06	6.01e-05	CbGpPWpGaD
Clonidine—CYP1A2—Metabolism—GSTM1—liver cancer	8.09e-06	5.96e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling by GPCR—HRAS—liver cancer	8.07e-06	5.95e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—CDKN1B—liver cancer	8.06e-06	5.94e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—PIK3CD—liver cancer	8e-06	5.9e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—MMP9—liver cancer	7.99e-06	5.89e-05	CbGpPWpGaD
Clonidine—ADRA2C—GPCR downstream signaling—AKT1—liver cancer	7.97e-06	5.87e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—CDKN1A—liver cancer	7.96e-06	5.87e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—VEGFA—liver cancer	7.95e-06	5.86e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—CDKN1B—liver cancer	7.93e-06	5.85e-05	CbGpPWpGaD
Clonidine—ADRA2A—GPCR downstream signaling—PIK3CA—liver cancer	7.93e-06	5.84e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—SERPINE1—liver cancer	7.91e-06	5.83e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—CASP3—liver cancer	7.9e-06	5.82e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—IL2—liver cancer	7.89e-06	5.81e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—STAT3—liver cancer	7.87e-06	5.8e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling by GPCR—IL6—liver cancer	7.85e-06	5.78e-05	CbGpPWpGaD
Clonidine—ADRA1B—GPCR downstream signaling—AKT1—liver cancer	7.85e-06	5.78e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling by GPCR—KRAS—liver cancer	7.83e-06	5.77e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—CASP3—liver cancer	7.77e-06	5.73e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—MAPK8—liver cancer	7.77e-06	5.73e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—IL2—liver cancer	7.76e-06	5.72e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling by GPCR—AKT1—liver cancer	7.75e-06	5.71e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling by GPCR—PIK3CA—liver cancer	7.75e-06	5.71e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling by GPCR—IL6—liver cancer	7.72e-06	5.69e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—CYCS—liver cancer	7.71e-06	5.68e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—RAF1—liver cancer	7.69e-06	5.67e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—CCND1—liver cancer	7.69e-06	5.67e-05	CbGpPWpGaD
Clonidine—CYP1A2—Metabolism—CYP1A1—liver cancer	7.67e-06	5.65e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—JUN—liver cancer	7.67e-06	5.65e-05	CbGpPWpGaD
Clonidine—CYP3A5—Metabolism—PIK3CB—liver cancer	7.64e-06	5.63e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—CTNNB1—liver cancer	7.61e-06	5.61e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—GOT1—liver cancer	7.57e-06	5.58e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—GGT1—liver cancer	7.57e-06	5.58e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—CCND1—liver cancer	7.57e-06	5.58e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—JUN—liver cancer	7.55e-06	5.56e-05	CbGpPWpGaD
Clonidine—ABCB1—Metabolism—PIK3CG—liver cancer	7.53e-06	5.55e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—MTOR—liver cancer	7.51e-06	5.53e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—PIK3CB—liver cancer	7.51e-06	5.53e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—CTNNB1—liver cancer	7.49e-06	5.52e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—MMP9—liver cancer	7.46e-06	5.5e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—CDKN1A—liver cancer	7.44e-06	5.48e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—MMP9—liver cancer	7.35e-06	5.41e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—CDKN1A—liver cancer	7.32e-06	5.39e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—MYC—liver cancer	7.31e-06	5.39e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—TGFB1—liver cancer	7.29e-06	5.38e-05	CbGpPWpGaD
Clonidine—ABCB1—Metabolism—PPARG—liver cancer	7.27e-06	5.35e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—MAPK8—liver cancer	7.26e-06	5.35e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling by GPCR—AKT1—liver cancer	7.24e-06	5.33e-05	CbGpPWpGaD
Clonidine—CYP1A1—Metabolism—PIK3CB—liver cancer	7.22e-06	5.32e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling by GPCR—PIK3CA—liver cancer	7.2e-06	5.3e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—VEGFA—liver cancer	7.18e-06	5.29e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling by GPCR—HRAS—liver cancer	7.17e-06	5.28e-05	CbGpPWpGaD
Clonidine—CYP1A2—Metabolism—MTHFR—liver cancer	7.15e-06	5.27e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—MAPK8—liver cancer	7.14e-06	5.26e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—RAF1—liver cancer	7.14e-06	5.26e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling by GPCR—AKT1—liver cancer	7.12e-06	5.25e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—STAT3—liver cancer	7.1e-06	5.24e-05	CbGpPWpGaD
Clonidine—CYP2D6—Metabolism—PIK3CG—liver cancer	7.09e-06	5.23e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—CDKN1B—liver cancer	7.04e-06	5.19e-05	CbGpPWpGaD
Clonidine—CYP1A2—Metabolism—PPARA—liver cancer	7.02e-06	5.17e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—PIK3CB—liver cancer	6.97e-06	5.14e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—MTOR—liver cancer	6.97e-06	5.14e-05	CbGpPWpGaD
Clonidine—ADRA1A—GPCR downstream signaling—AKT1—liver cancer	6.97e-06	5.14e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—CASP3—liver cancer	6.9e-06	5.09e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—IL2—liver cancer	6.89e-06	5.08e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling by GPCR—IL6—liver cancer	6.86e-06	5.06e-05	CbGpPWpGaD
Clonidine—CYP2D6—Metabolism—PPARG—liver cancer	6.85e-06	5.05e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—GSTP1—liver cancer	6.8e-06	5.01e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—KRAS—liver cancer	6.76e-06	4.98e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—CCND1—liver cancer	6.72e-06	4.95e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—JUN—liver cancer	6.71e-06	4.94e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—HMOX1—liver cancer	6.7e-06	4.94e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—VEGFA—liver cancer	6.7e-06	4.94e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling by GPCR—HRAS—liver cancer	6.66e-06	4.91e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—CTNNB1—liver cancer	6.66e-06	4.9e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—STAT3—liver cancer	6.64e-06	4.89e-05	CbGpPWpGaD
Clonidine—ABCB1—Metabolism—PIK3CD—liver cancer	6.62e-06	4.88e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—MYC—liver cancer	6.6e-06	4.87e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—VEGFA—liver cancer	6.6e-06	4.86e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—TGFB1—liver cancer	6.59e-06	4.85e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	6.55e-06	4.82e-05	CbGpPWpGaD
Clonidine—ABCB1—Metabolism—ALB—liver cancer	6.53e-06	4.81e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—STAT3—liver cancer	6.53e-06	4.81e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—MMP9—liver cancer	6.52e-06	4.81e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—CDKN1A—liver cancer	6.5e-06	4.79e-05	CbGpPWpGaD
Clonidine—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	6.47e-06	4.77e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—CASP3—liver cancer	6.42e-06	4.73e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—IL2—liver cancer	6.41e-06	4.72e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling by GPCR—IL6—liver cancer	6.37e-06	4.7e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—MAPK8—liver cancer	6.35e-06	4.68e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling by GPCR—AKT1—liver cancer	6.33e-06	4.66e-05	CbGpPWpGaD
Clonidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.3e-06	4.65e-05	CbGpPWpGaD
Clonidine—ADRA2C—Metabolism—PIK3CA—liver cancer	6.26e-06	4.61e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—GSTM1—liver cancer	6.25e-06	4.6e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—CCND1—liver cancer	6.24e-06	4.6e-05	CbGpPWpGaD
Clonidine—CYP2D6—Metabolism—PIK3CD—liver cancer	6.24e-06	4.6e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—JUN—liver cancer	6.23e-06	4.59e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—PIK3CA—liver cancer	6.21e-06	4.57e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	6.18e-06	4.56e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—MYC—liver cancer	6.17e-06	4.54e-05	CbGpPWpGaD
Clonidine—CYP2D6—Metabolism—ALB—liver cancer	6.16e-06	4.54e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—TGFB1—liver cancer	6.15e-06	4.53e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—KRAS—liver cancer	6.1e-06	4.5e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—MYC—liver cancer	6.07e-06	4.47e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—MMP9—liver cancer	6.06e-06	4.47e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—TGFB1—liver cancer	6.05e-06	4.46e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	6.04e-06	4.45e-05	CbGpPWpGaD
Clonidine—CYP1A2—Metabolism—PIK3CG—liver cancer	6.01e-06	4.43e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—TP53—liver cancer	6e-06	4.43e-05	CbGpPWpGaD
Clonidine—SLC22A1—Metabolism—PIK3CA—liver cancer	6e-06	4.42e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—CYP1A1—liver cancer	5.92e-06	4.36e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—MAPK8—liver cancer	5.9e-06	4.35e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling by GPCR—AKT1—liver cancer	5.88e-06	4.33e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—VEGFA—liver cancer	5.86e-06	4.32e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—STAT3—liver cancer	5.8e-06	4.28e-05	CbGpPWpGaD
Clonidine—CYP1A2—Metabolism—PPARG—liver cancer	5.8e-06	4.27e-05	CbGpPWpGaD
Clonidine—ABCB1—Metabolism—PIK3CB—liver cancer	5.77e-06	4.25e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—HRAS—liver cancer	5.74e-06	4.23e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—KRAS—liver cancer	5.7e-06	4.2e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—KRAS—liver cancer	5.61e-06	4.13e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—PIK3CA—liver cancer	5.6e-06	4.13e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—MTHFR—liver cancer	5.52e-06	4.07e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—IL6—liver cancer	5.5e-06	4.05e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—VEGFA—liver cancer	5.44e-06	4.01e-05	CbGpPWpGaD
Clonidine—CYP2D6—Metabolism—PIK3CB—liver cancer	5.44e-06	4.01e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—TP53—liver cancer	5.42e-06	4e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—PPARA—liver cancer	5.42e-06	3.99e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—MYC—liver cancer	5.39e-06	3.97e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—STAT3—liver cancer	5.39e-06	3.97e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—TGFB1—liver cancer	5.38e-06	3.96e-05	CbGpPWpGaD
Clonidine—CYP1A2—Metabolism—PIK3CD—liver cancer	5.28e-06	3.89e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—PIK3CA—liver cancer	5.23e-06	3.86e-05	CbGpPWpGaD
Clonidine—CYP1A2—Metabolism—ALB—liver cancer	5.22e-06	3.84e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—HRAS—liver cancer	5.18e-06	3.82e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—PIK3CA—liver cancer	5.15e-06	3.8e-05	CbGpPWpGaD
Clonidine—ADRA2C—Metabolism—AKT1—liver cancer	5.11e-06	3.77e-05	CbGpPWpGaD
Clonidine—ADRA2A—Metabolism—PIK3CA—liver cancer	5.09e-06	3.75e-05	CbGpPWpGaD
Clonidine—ADRA1D—Signaling Pathways—AKT1—liver cancer	5.07e-06	3.74e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—TP53—liver cancer	5.06e-06	3.73e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—MYC—liver cancer	5.01e-06	3.69e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—TGFB1—liver cancer	5e-06	3.68e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—TP53—liver cancer	4.98e-06	3.67e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—KRAS—liver cancer	4.98e-06	3.67e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—IL6—liver cancer	4.96e-06	3.66e-05	CbGpPWpGaD
Clonidine—SLC22A1—Metabolism—AKT1—liver cancer	4.9e-06	3.61e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—HRAS—liver cancer	4.84e-06	3.57e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—HRAS—liver cancer	4.77e-06	3.51e-05	CbGpPWpGaD
Clonidine—CYP3A5—Metabolism—PIK3CA—liver cancer	4.66e-06	3.43e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—PIK3CG—liver cancer	4.64e-06	3.42e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—IL6—liver cancer	4.64e-06	3.42e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—KRAS—liver cancer	4.63e-06	3.41e-05	CbGpPWpGaD
Clonidine—CYP1A2—Metabolism—PIK3CB—liver cancer	4.6e-06	3.39e-05	CbGpPWpGaD
Clonidine—ADRA2B—Signaling Pathways—AKT1—liver cancer	4.58e-06	3.37e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—PIK3CA—liver cancer	4.58e-06	3.37e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—IL6—liver cancer	4.56e-06	3.36e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—PPARG—liver cancer	4.48e-06	3.3e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—TP53—liver cancer	4.43e-06	3.26e-05	CbGpPWpGaD
Clonidine—CYP1A1—Metabolism—PIK3CA—liver cancer	4.4e-06	3.24e-05	CbGpPWpGaD
Clonidine—ADRA2C—Signaling Pathways—AKT1—liver cancer	4.28e-06	3.15e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	4.25e-06	3.13e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—HRAS—liver cancer	4.23e-06	3.12e-05	CbGpPWpGaD
Clonidine—ADRA1B—Signaling Pathways—AKT1—liver cancer	4.21e-06	3.1e-05	CbGpPWpGaD
Clonidine—ADRA2A—Metabolism—AKT1—liver cancer	4.15e-06	3.06e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—TP53—liver cancer	4.11e-06	3.03e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—PIK3CD—liver cancer	4.08e-06	3e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—IL6—liver cancer	4.05e-06	2.99e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—ALB—liver cancer	4.02e-06	2.97e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—HRAS—liver cancer	3.93e-06	2.9e-05	CbGpPWpGaD
Clonidine—CYP3A5—Metabolism—AKT1—liver cancer	3.81e-06	2.81e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—IL6—liver cancer	3.77e-06	2.77e-05	CbGpPWpGaD
Clonidine—ADRA1A—Signaling Pathways—AKT1—liver cancer	3.74e-06	2.76e-05	CbGpPWpGaD
Clonidine—CYP1A1—Metabolism—AKT1—liver cancer	3.6e-06	2.65e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—PIK3CB—liver cancer	3.55e-06	2.62e-05	CbGpPWpGaD
Clonidine—ABCB1—Metabolism—PIK3CA—liver cancer	3.52e-06	2.59e-05	CbGpPWpGaD
Clonidine—ADRA2A—Signaling Pathways—AKT1—liver cancer	3.47e-06	2.56e-05	CbGpPWpGaD
Clonidine—CYP2D6—Metabolism—PIK3CA—liver cancer	3.31e-06	2.44e-05	CbGpPWpGaD
Clonidine—ABCB1—Metabolism—AKT1—liver cancer	2.87e-06	2.12e-05	CbGpPWpGaD
Clonidine—CYP1A2—Metabolism—PIK3CA—liver cancer	2.81e-06	2.07e-05	CbGpPWpGaD
Clonidine—CYP2D6—Metabolism—AKT1—liver cancer	2.71e-06	1.99e-05	CbGpPWpGaD
Clonidine—CYP1A2—Metabolism—AKT1—liver cancer	2.29e-06	1.69e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—PIK3CA—liver cancer	2.17e-06	1.6e-05	CbGpPWpGaD
Clonidine—CYP3A4—Metabolism—AKT1—liver cancer	1.77e-06	1.3e-05	CbGpPWpGaD
